Anavex Life Sciences (AVXL) 0.9100 $AVXL
Valuation Gets A Boost After Growth In Supplement & Wellness Stocks
ACCESSWIRE - Mon Jul 27, 7:01AM CDT
CORAL GABLES, FL / ACCESSWIRE / July 27, 2015 / The Vitamin and Supplement Manufacturing industry growth has seen incredible expansion over the last half decade. Increased demands from a larger mainstream, health-conscious customer base and the growth of the aging baby boomer population have been two main contributors to the rise of this market. IBIS World estimates that in the years ahead, the industry will benefit from the same trends that have supported its growth in the past. These include rising health spending as well as growing interest in wellness and nutrition among mainstream consumers. Reports from the research firm show that the market is growing at an annual rate of 7% and is currently worth $18 billion. Companies concentrated in this market have seen increased attention in 2015. That Marketing Solution Inc. (OTC: TSTS), International Sustainability Group, Inc. (OTC: ISGP), and Anavex Life Sciences Corp. (OTC: AVXL) are among the companies seeing higher levels of volume and price movement during the summer months.
Free Penny Stocks Alerts for Alpha Natural Resources, WINDSTREAM, Global Equity, Liquidmetal, Anavex Life Sciences, and Thinspace
PR Newswire - Fri Jul 24, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Alpha Natural Resources (OTCMKTS:ANRZ), WINDSTREAM (OTCMKTS:WSTI), Global Equity (OTCBB:GEQU), Liquidmetal (OTCMKTS:LQMT), Anavex Life Sciences (OTCMKTS:AVXL), and Thinspace (OTCMKTS:THNS).
Anavex Presents Positive Initial Phase 2a Study Data With ANAVEX 2-73 Showing Early Evidence of Improving Cognition in Patients With Alzheimer's Disease at AAIC 2015
GlobeNewswire - Wed Jul 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL) today announced initial positive cognitive data for ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's targeting sigma-1 and muscarinic receptors, which is believed to reduce protein misfolding including reduction of beta amyloid, tau and inflammation. Cognitive EEG/ERP P300 data, a real-time physiological measure of cognitive processes with demonstrated sensitivity to Alzheimer's disease, is being presented today for the first 12 of 32 mild-to-moderate Alzheimer's patients in the ongoing ANAVEX 2-73 Phase 2a clinical trial at AAIC 2015 in Washington, DC.
Biopharmaceuticals - Global Strategic Business Report 2015: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines
M2 - Wed Jul 15, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/36r3rv/biopharmaceuticals) has announced the addition of the "Biopharmaceuticals - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Biopharmaceuticals in US$ Million by the following Segments: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 514 companies including many key and niche players such as: - AbbVie, Inc. (US) - Anavex Life Sciences Corp. (US) - Baxter International, Inc. (US) - Bayer HealthCare Pharmaceuticals, Inc. (US) - Biocon (India) - Eli Lilly (US) - F. Hoffmann-La Roche Ltd. (Switzerland) - Genentech (US) - GlaxoSmithKline (UK) - Janssen Biotech, Inc. (US) - Kemwell Biopharma (India) - Novartis (Switzerland) - Sandoz - Pfizer, Inc. (US) - Sun Pharmaceutical Industries Ltd. (India) - Sanofi S.A. (France) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. SEGMENT ANALYSIS 3. BIOPHARMACEUTICALS IN THE PIPELINE 4. MARKET TRENDS 5. BIOPHARMACEUTICALS 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT GLOBAL PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 514 (including Divisions/Subsidiaries 525) - The United States (300) - Canada (14) - Japan (5) - Europe (137) - - France (21) - - Germany (21) - - The United Kingdom (12) - - Italy (5) - - Spain (3) - - Rest of Europe (75) - Asia-Pacific (Excluding Japan) (60) - Middle East (9) For more information visit http://www.researchandmarkets.com/research/36...aceuticals
BAX: 37.70 (+0.06), PFE: 34.34 (+0.08), LLY: 84.15 (-0.57), ABBV: 69.34 (+1.26), GSK: 41.60 (+0.21), NVS: 101.54 (-0.26)
Penny Stocks Research for Thinspace, Pharmacyte Biotech, MaryJane, TOTALLY HEMP CRAZY, EKSO BIONICS, and Anavex Life Sciences
PR Newswire - Fri Jul 10, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Thinspace (OTCMKTS:THNS), Pharmacyte Biotech (OTCMKTS
MCB), MaryJane (OTCMKTS:MJMJ), TOTALLY HEMP CRAZY (OTCMKTS:THCZ), EKSO BIONICS (OTCBB:EKSO), and Anavex Life Sciences (OTCMKTS:AVXL).
Anavex to Present Initial Clinical Data From the Phase 2a Clinical Trial of ANAVEX 2-73 at the Alzheimer's Association International Conference (AAIC)
GlobeNewswire - Tue Jun 30, 6:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of initial clinical data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 during the upcoming Alzheimer's Association International Conference(R) 2015 (AAIC), which takes place in Washington D.C. from July 18-23, 2015.
Anavex Strengthens Board of Directors
GlobeNewswire - Thu Jun 18, 6:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the appointment of Steffen Thomas, PhD, to its Board of Directors. Dr. Thomas has 15 years of experience in intellectual property, patent law and proprietary technology rights as well as significant expertise in small molecule pharmaceuticals.
Global Acute Pain Pipeline Report 2015
M2 - Thu Jun 04, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gndxls/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt plc - MEDRx Co., Ltd. - Merck & Co., Inc. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Rottapharm SpA - Santen Pharmaceutical Co., Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. - Thar Pharmaceuticals, Inc. - Trevena, Inc. - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/gndxls/acute_pain
ACRX: 4.08 (-0.34), TRVN: 6.21 (-0.28), KMPH: 17.04 (-0.55), MRK: 56.99 (-0.42), PCRX: 59.50 (-2.81), NKTR: 12.42 (-0.36)
Anavex Encouraged by Data Showing Sigma-1 Receptor Reduces Tau Dysfunction, a Hallmark of Alzheimer's Disease
M2 - Thu May 21, 10:35AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, is encouraged by recent data published in the Proceedings of the National Academy of Sciences. The research determines that activating the sigma-1 receptor with agonists can potentially reduce the devastating impact of tau dysfunction. Abnormal tau phosphorylation is a common characteristic in multiple neurodegenerative diseases. Alzheimer's is the most widely recognized neurodegenerative disease associated with the aggregation of tau protein in the brain, with others including progressive supranuclear palsy (PSP) and frontotemporal dementia. It has been previously reported that ANAVEX 2-73, targeting the sigma-1 receptor in a dose-dependent study, blocked tau and amyloid-beta ("amyloid" proteins as well as memory deficits in a mouse model of Alzheimer's disease. This data was published in the international scientific journal Neuropsychopharmacology. A reduction in these two main hallmarks of Alzheimer's has the potential to stop, slow or reverse the disease. ANAVEX 2-73 is currently in a Phase 2a study for Alzheimer's disease, and the Company expects to report preliminary data around the Q3 2015 timeframe.
Anavex Releases Promising Full Preclinical Epilepsy Data at Antiepileptic Drug Trials XIII Conference
M2 - Mon May 18, 10:46AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, revealed full preclinical anti-seizure data for its lead drug candidate, ANAVEX 2-73, in a presentation on Friday, May 15, 2015 at the Antiepileptic Drug Trials XIII Conference. ANAVEX 2-73 demonstrated convincing data in three well-established and according to experts highly predictive preclinical anti-seizure models with potentially more favorable side effect profile than currently marketed epilepsy drugs. The cognitive-enhancing features of ANAVEX 2-73 might be a differentiating factor since seizures cause neuro-cognitive impairments, which can be worsened by current epilepsy medications. The strong performance of ANAVEX 2-73 was also confirmed in combination with three generations of epilepsy drugs currently on the market.
Anavex Reports Fiscal Second Quarter 2015 Financial Results
M2 - Fri May 15, 11:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2015.
Anavex to Present at 2015 Marcum Conference on May 27th
GlobeNewswire - Wed May 13, 7:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 2015 Marcum Microcap Conference on Wednesday, May 27, 2015 at 3:30 p.m. ET in the Winter Garden room at the Grand Hyatt New York.
Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference
M2 - Thu Apr 23, 10:07AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the World Orphan Drug Congress on Thursday, April 23, 2015 at 11:10 a.m. ET at The Washington Hilton in Washington, DC. In a presentation titled "Potential applications of sigma-1 receptors in orphan indications," Dr. Missling will discuss the role of sigma-1 receptors in additional indications beyond Alzheimer's disease.
Anavex Life Sciences Analyst Coverage Initiated: Report Issued by BrokerBank Securities, Inc.
PR Newswire - Thu Apr 23, 6:00AM CDT
Anavex Life Science Corp. (OTCMKTS: AVXL) was incorporated on January 23, 2004. The company's lead compounds include ANAVEX 2-73, ANAVEX PLUS, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer's disease and other central nervous system diseases.
Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain
M2 - Tue Apr 07, 9:43AM CDT
Report Further Validates Therapeutic Application of Proprietary Anavex Compounds in Multiple Neurological Diseases
Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain Injuries
GlobeNewswire - Tue Apr 07, 7:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL) is encouraged by the findings of a new report in the latest issue of peer-reviewed scientific journal Neuroscience Letters. The study demonstrates for the first time through real-time in vivo imaging how microglial inflammation, which is involved in devastating neurodegenerative diseases, can be resolved by sigma-1 receptor activation. The role of sigma-1 receptor activation is to reduce the negative response caused by chronic microglia over-activation, which leads to widespread cell death and multiple neurodegenerative diseases, from brain injury to Alzheimer's disease.
Valuation Gets A Boost After Growth In Supplement & Wellness Stocks
ACCESSWIRE - Mon Jul 27, 7:01AM CDT
CORAL GABLES, FL / ACCESSWIRE / July 27, 2015 / The Vitamin and Supplement Manufacturing industry growth has seen incredible expansion over the last half decade. Increased demands from a larger mainstream, health-conscious customer base and the growth of the aging baby boomer population have been two main contributors to the rise of this market. IBIS World estimates that in the years ahead, the industry will benefit from the same trends that have supported its growth in the past. These include rising health spending as well as growing interest in wellness and nutrition among mainstream consumers. Reports from the research firm show that the market is growing at an annual rate of 7% and is currently worth $18 billion. Companies concentrated in this market have seen increased attention in 2015. That Marketing Solution Inc. (OTC: TSTS), International Sustainability Group, Inc. (OTC: ISGP), and Anavex Life Sciences Corp. (OTC: AVXL) are among the companies seeing higher levels of volume and price movement during the summer months.
Free Penny Stocks Alerts for Alpha Natural Resources, WINDSTREAM, Global Equity, Liquidmetal, Anavex Life Sciences, and Thinspace
PR Newswire - Fri Jul 24, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Alpha Natural Resources (OTCMKTS:ANRZ), WINDSTREAM (OTCMKTS:WSTI), Global Equity (OTCBB:GEQU), Liquidmetal (OTCMKTS:LQMT), Anavex Life Sciences (OTCMKTS:AVXL), and Thinspace (OTCMKTS:THNS).
Anavex Presents Positive Initial Phase 2a Study Data With ANAVEX 2-73 Showing Early Evidence of Improving Cognition in Patients With Alzheimer's Disease at AAIC 2015
GlobeNewswire - Wed Jul 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL) today announced initial positive cognitive data for ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's targeting sigma-1 and muscarinic receptors, which is believed to reduce protein misfolding including reduction of beta amyloid, tau and inflammation. Cognitive EEG/ERP P300 data, a real-time physiological measure of cognitive processes with demonstrated sensitivity to Alzheimer's disease, is being presented today for the first 12 of 32 mild-to-moderate Alzheimer's patients in the ongoing ANAVEX 2-73 Phase 2a clinical trial at AAIC 2015 in Washington, DC. Biopharmaceuticals - Global Strategic Business Report 2015: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines
M2 - Wed Jul 15, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/36r3rv/biopharmaceuticals) has announced the addition of the "Biopharmaceuticals - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Biopharmaceuticals in US$ Million by the following Segments: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 514 companies including many key and niche players such as: - AbbVie, Inc. (US) - Anavex Life Sciences Corp. (US) - Baxter International, Inc. (US) - Bayer HealthCare Pharmaceuticals, Inc. (US) - Biocon (India) - Eli Lilly (US) - F. Hoffmann-La Roche Ltd. (Switzerland) - Genentech (US) - GlaxoSmithKline (UK) - Janssen Biotech, Inc. (US) - Kemwell Biopharma (India) - Novartis (Switzerland) - Sandoz - Pfizer, Inc. (US) - Sun Pharmaceutical Industries Ltd. (India) - Sanofi S.A. (France) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. SEGMENT ANALYSIS 3. BIOPHARMACEUTICALS IN THE PIPELINE 4. MARKET TRENDS 5. BIOPHARMACEUTICALS 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT GLOBAL PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 514 (including Divisions/Subsidiaries 525) - The United States (300) - Canada (14) - Japan (5) - Europe (137) - - France (21) - - Germany (21) - - The United Kingdom (12) - - Italy (5) - - Spain (3) - - Rest of Europe (75) - Asia-Pacific (Excluding Japan) (60) - Middle East (9) For more information visit http://www.researchandmarkets.com/research/36...aceuticals
BAX: 37.70 (+0.06), PFE: 34.34 (+0.08), LLY: 84.15 (-0.57), ABBV: 69.34 (+1.26), GSK: 41.60 (+0.21), NVS: 101.54 (-0.26)
Penny Stocks Research for Thinspace, Pharmacyte Biotech, MaryJane, TOTALLY HEMP CRAZY, EKSO BIONICS, and Anavex Life Sciences
PR Newswire - Fri Jul 10, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Thinspace (OTCMKTS:THNS), Pharmacyte Biotech (OTCMKTS
MCB), MaryJane (OTCMKTS:MJMJ), TOTALLY HEMP CRAZY (OTCMKTS:THCZ), EKSO BIONICS (OTCBB:EKSO), and Anavex Life Sciences (OTCMKTS:AVXL). Anavex to Present Initial Clinical Data From the Phase 2a Clinical Trial of ANAVEX 2-73 at the Alzheimer's Association International Conference (AAIC)
GlobeNewswire - Tue Jun 30, 6:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of initial clinical data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 during the upcoming Alzheimer's Association International Conference(R) 2015 (AAIC), which takes place in Washington D.C. from July 18-23, 2015. Anavex Strengthens Board of Directors
GlobeNewswire - Thu Jun 18, 6:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the appointment of Steffen Thomas, PhD, to its Board of Directors. Dr. Thomas has 15 years of experience in intellectual property, patent law and proprietary technology rights as well as significant expertise in small molecule pharmaceuticals. Global Acute Pain Pipeline Report 2015
M2 - Thu Jun 04, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gndxls/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt plc - MEDRx Co., Ltd. - Merck & Co., Inc. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Rottapharm SpA - Santen Pharmaceutical Co., Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. - Thar Pharmaceuticals, Inc. - Trevena, Inc. - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/gndxls/acute_pain
ACRX: 4.08 (-0.34), TRVN: 6.21 (-0.28), KMPH: 17.04 (-0.55), MRK: 56.99 (-0.42), PCRX: 59.50 (-2.81), NKTR: 12.42 (-0.36)
Anavex Encouraged by Data Showing Sigma-1 Receptor Reduces Tau Dysfunction, a Hallmark of Alzheimer's Disease
M2 - Thu May 21, 10:35AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, is encouraged by recent data published in the Proceedings of the National Academy of Sciences. The research determines that activating the sigma-1 receptor with agonists can potentially reduce the devastating impact of tau dysfunction. Abnormal tau phosphorylation is a common characteristic in multiple neurodegenerative diseases. Alzheimer's is the most widely recognized neurodegenerative disease associated with the aggregation of tau protein in the brain, with others including progressive supranuclear palsy (PSP) and frontotemporal dementia. It has been previously reported that ANAVEX 2-73, targeting the sigma-1 receptor in a dose-dependent study, blocked tau and amyloid-beta ("amyloid" proteins as well as memory deficits in a mouse model of Alzheimer's disease. This data was published in the international scientific journal Neuropsychopharmacology. A reduction in these two main hallmarks of Alzheimer's has the potential to stop, slow or reverse the disease. ANAVEX 2-73 is currently in a Phase 2a study for Alzheimer's disease, and the Company expects to report preliminary data around the Q3 2015 timeframe. Anavex Releases Promising Full Preclinical Epilepsy Data at Antiepileptic Drug Trials XIII Conference
M2 - Mon May 18, 10:46AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, revealed full preclinical anti-seizure data for its lead drug candidate, ANAVEX 2-73, in a presentation on Friday, May 15, 2015 at the Antiepileptic Drug Trials XIII Conference. ANAVEX 2-73 demonstrated convincing data in three well-established and according to experts highly predictive preclinical anti-seizure models with potentially more favorable side effect profile than currently marketed epilepsy drugs. The cognitive-enhancing features of ANAVEX 2-73 might be a differentiating factor since seizures cause neuro-cognitive impairments, which can be worsened by current epilepsy medications. The strong performance of ANAVEX 2-73 was also confirmed in combination with three generations of epilepsy drugs currently on the market. Anavex Reports Fiscal Second Quarter 2015 Financial Results
M2 - Fri May 15, 11:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2015. Anavex to Present at 2015 Marcum Conference on May 27th
GlobeNewswire - Wed May 13, 7:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 2015 Marcum Microcap Conference on Wednesday, May 27, 2015 at 3:30 p.m. ET in the Winter Garden room at the Grand Hyatt New York. Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference
M2 - Thu Apr 23, 10:07AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the World Orphan Drug Congress on Thursday, April 23, 2015 at 11:10 a.m. ET at The Washington Hilton in Washington, DC. In a presentation titled "Potential applications of sigma-1 receptors in orphan indications," Dr. Missling will discuss the role of sigma-1 receptors in additional indications beyond Alzheimer's disease. Anavex Life Sciences Analyst Coverage Initiated: Report Issued by BrokerBank Securities, Inc.
PR Newswire - Thu Apr 23, 6:00AM CDT
Anavex Life Science Corp. (OTCMKTS: AVXL) was incorporated on January 23, 2004. The company's lead compounds include ANAVEX 2-73, ANAVEX PLUS, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer's disease and other central nervous system diseases.
Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain
M2 - Tue Apr 07, 9:43AM CDT
Report Further Validates Therapeutic Application of Proprietary Anavex Compounds in Multiple Neurological Diseases
Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain Injuries
GlobeNewswire - Tue Apr 07, 7:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL) is encouraged by the findings of a new report in the latest issue of peer-reviewed scientific journal Neuroscience Letters. The study demonstrates for the first time through real-time in vivo imaging how microglial inflammation, which is involved in devastating neurodegenerative diseases, can be resolved by sigma-1 receptor activation. The role of sigma-1 receptor activation is to reduce the negative response caused by chronic microglia over-activation, which leads to widespread cell death and multiple neurodegenerative diseases, from brain injury to Alzheimer's disease. 
